Signet Therapeutics Honored as 'Annual Rising Star Enterprise' by Securities Times, Files IPO Prospectus

Recently, the 12th Venture Capital Forum and the China Venture Capital Association Alliance's event in Shanghai Zhangjiang, themed "Innovation Empowers, Born Anew," was grandly held. During the event, the results of the "Annual Rising Enterprise" evaluation hosted by the Securities Times were officially announced after rounds of selection.SIGNET Honored with "New Enterprise of the Year" Award。

Securities Times, a mainstream financial media outlet under the supervision and management of the People's Daily, has long been focusing on the development of emerging industries. Its multi-session venture capital forums have been widely recognized by regulatory authorities, the venture capital community, and listed companies, among other participants in the capital market. The selection process for this award lasted three months, involving rigorous application procedures, expert evaluations, and fierce competition among over 300 institutions and enterprises. Ultimately, a group of companies with unlimited potential and vitality emerged victorious.

This award win heralds SIGNET's boundless potential for future development in the biopharmaceutical field. In just over three years, SIGNET has obtained the world's first FDA IND approval for a targeted drug for diffuse gastric cancer. Several other pipelines are also rapidly advancing toward clinical trials. In the future, SIGNET will continue to fill clinical gaps and bring more good news to patients.

Signet Therapeutics is the first company in China to develop innovative targeted cancer drugs based on organoid disease models and AI. It was initially founded on the Harvard University campus, established in Shenzhen in 2020, and completed an angel round of financing worth nearly 150 million yuan within a year. Signet is not only a transliteration of "Signet" but also adheres to the vision of "Hopeful Hearts, Knowledge through Investigation." The company leverages organoid disease models that closely resemble patients' genomic characteristics for efficacy evaluation and new target discovery, combined with AI-powered screening, synthesis, and optimization of small molecule compounds to develop first-in-class innovative targeted drugs. Currently, the company has three drug pipelines, a 1,200-square-meter R&D facility, and a 500-square-meter animal laboratory space. Signet Therapeutics' disease model platform serves not only its own drug pipelines but also actively empowers large pharmaceutical companies in new drug development, facilitating the birth of more innovative drugs.